The Hijacked Brain: One Person’s Journey Through the Long Night of Opioid Addiction and the Science of a New Dawn

Introduction: The First Dose

It began, as it so often does, not in a shadowed alley but under the bright, sterile lights of a doctor’s office. Alex was seventeen, a high school athlete whose world revolved around the crisp autumn air of the football field, the roar of the crowd, and the satisfying ache of a body pushed to its limits. That world fractured with the sickening pop in his knee during a tackle. The physical pain was sharp, a searing message of torn ligaments and a season cut short. But beneath it lay a deeper ache: the anxiety of a future suddenly uncertain, the loss of identity, the quiet dread of being left behind.¹

The doctor, a kind man with tired eyes, reviewed the MRI and wrote a prescription. The name on the pad was OxyContin. He explained it was a powerful, state-of-the-art painkiller, uniquely formulated to provide steady, round-the-clock relief. It was safe, he assured Alex and his mother, because its special coating was designed for slow release, making it far less prone to abuse or addiction than older painkillers.³ The first dose was a revelation. The fire in his knee subsided to a distant warmth. But something else happened, too. The gnawing anxiety, the teenage angst he hadn’t even fully registered, dissolved into a soft, floating calm. It was more than the absence of pain; it was the presence of a profound, effortless well-being, a gentle euphoria that smoothed the raw edges of his upended life.⁵ For a young man adrift in a sea of pain and disappointment, it felt like a lifeline. He had no way of knowing it was an anchor, poised to drag him into the abyss.

Alex’s story, in its mundane and tragic beginnings, is not his alone. It is the story of millions, the foundational narrative of a public health catastrophe that was not an accident of history but the result of a meticulously engineered plan. To understand how a single prescription could become the first step on a path to ruin, one must look back to the 1990s, when the first wave of what would become the opioid crisis began to crest. It was a wave of death driven by prescription opioids, a phenomenon that saw the rate of overdose deaths in the United States involving these drugs increase five-fold from the late 1990s onward.⁷

This crisis was not born of a sudden, spontaneous surge in illicit drug use. It was iatrogenic—a sickness induced by the very medical system entrusted with healing. At its epicenter was a single company, Purdue Pharma, and the secretive, powerful family that owned it: the Sacklers.³ Drawing on a playbook pioneered by the family patriarch, Dr. Arthur Sackler—a man celebrated as the father of modern pharmaceutical advertising—Purdue launched OxyContin in 1996 with a marketing campaign of unprecedented aggression and breathtaking fraudulence.³ The company’s sales force, armed with misleading data and seductive messaging, descended upon doctors’ offices across America with a single, revolutionary claim: that due to its patented slow-release mechanism, the risk of addiction to OxyContin was “less than 1 percent”.³

This assertion was the cornerstone of a campaign to fundamentally change the culture of pain management in America. For decades, physicians had harbored a healthy and well-founded fear of prescribing strong opioids for anything other than acute, short-term pain or end-of-life cancer care, precisely because of their high potential for addiction.³ Purdue’s mission was to dismantle that caution. They sought to persuade the entire medical establishment that these fears were overblown, that pain was an undertreated “fifth vital sign,” and that OxyContin was the safe, long-term solution.³ Internal documents and emails later revealed the chilling calculus behind this strategy. The company knew that the market for cancer pain was limited; the real profits lay in the vast, untapped market of chronic noncancer pain—back pain, arthritis, fibromyalgia.³ They consciously chose not to correct doctors’ misperceptions that oxycodone was weaker than morphine when, in fact, it is significantly stronger.³ They downplayed the risks and wildly exaggerated the benefits, creating a new medical consensus out of thin air, all in the service of profit.³

The strategy was a staggering success. Prescriptions soared, and Purdue Pharma and the Sackler family reaped billions of dollars in profits.⁴ But the consequences were catastrophic. The widespread belief that prescription opioids were fundamentally safer than “street drugs” like heroin became deeply entrenched, a myth that ignored a simple neurochemical fact: in the brain, the effects of oxycodone are indistinguishable from those of heroin.¹² Other companies soon followed Purdue’s lead, with some, like Insys Therapeutics, escalating the tactics to include outright bribery of doctors and systemic insurance fraud to push their own hyper-potent fentanyl products.¹⁴

Alex, holding his first bottle of OxyContin, was a product of this manufactured reality. His doctor was not malicious; he was a well-intentioned physician acting on what he had been aggressively taught was the new standard of care. The trust inherent in the doctor-patient relationship had been weaponized. The prescription was not just a tool for pain relief; it was the delivery mechanism for a corporate strategy, the end point of a chain of influence that began in a corporate boardroom. Alex was not simply a patient who would become an addict. He was, from the moment that prescription was filled, the victim of a public health disaster engineered for private gain. He was about to learn, in the most intimate and brutal way possible, the true, long-term effects of the drug he had been told would heal him.

Part I: The Struggle – A World in Monochrome

Chapter 1: The Invisible Hook: The Neurobiology of Dependence

For the first few weeks, the pills were a miracle. Alex followed the prescription meticulously, and the drug did its job, holding his surgical pain at bay. But he also noticed the other effect—that warm, placid feeling that erased his worries. Soon, he found himself looking forward to the next dose not just for the pain relief, but for the mental escape.⁵ When the prescription ran out, the pain in his knee had mostly subsided, but a new, more insidious ache had taken its place: a craving. He called the doctor, exaggerating his pain, and got a refill. This was the first conscious deception, the first time he prioritized the drug’s psychological effect over medical necessity. It would not be the last.

What Alex was experiencing was not a failure of character or a weakness of will. It was the beginning of a hostile takeover of his brain’s most fundamental machinery. Opioid Use Disorder (OUD) is not a moral failing; it is a chronic, relapsing brain disease, defined by the compulsive use of opioids despite clinically significant distress and impairment.¹⁵ Long-term use of these substances doesn’t just influence behavior; it physically and functionally alters the brain, hijacking ancient neural circuits that were designed for survival and turning them against the self.¹⁸

The process begins in the brain’s reward system, an evolutionarily ancient pathway conserved across millions of years and countless species.²⁰ This system, which includes key structures like the Ventral Tegmental Area (VTA) and the Nucleus Accumbens (NAc), is designed to reinforce life-sustaining behaviors like eating, socializing, and procreating. It does this through the release of the neurotransmitter dopamine. When we engage in a rewarding activity, the VTA releases dopamine into the NAc, creating a feeling of pleasure and motivation that teaches the brain to repeat the behavior.¹⁸ Opioids short-circuit this natural process with brutal efficiency. When Alex took an OxyContin pill, the drug molecules crossed the blood-brain barrier and bound to mu-opioid receptors in his brain. This action triggered the VTA to release a massive, unnatural flood of dopamine into the NAc—a surge two to ten times greater than any natural reward could produce.¹⁶

This overwhelming dopamine signal is a powerful lesson for the brain. It constitutes a form of pathological learning, where the brain is tricked into believing that the drug is more important for survival than food, safety, or human connection.²⁰ With each dose, the neural pathways associated with drug-taking are strengthened. Simultaneously, the prefrontal cortex—the brain’s “CEO,” responsible for judgment, long-term planning, and impulse control—is progressively weakened and compromised.¹⁸ The ability to weigh consequences and make rational decisions about using the drug begins to erode. The brain is being rewired to prioritize one thing above all else: getting more of the drug.

As Alex continued to use, his brain began to adapt to the constant chemical onslaught. To protect itself from the toxic overstimulation, it initiated a process of downregulation. It started producing less of its own dopamine and reduced the number of available dopamine receptors.¹⁶ This is the neurobiological basis of tolerance.¹⁵ The initial dose no longer produced the same euphoric rush. Alex found he needed to take more pills, and more frequently, just to feel the same effect. He began crushing the pills to bypass the time-release mechanism, getting a faster, more intense high—a common practice that Purdue Pharma was aware of for years while continuing to claim the drug was less abusable.

This escalating use cemented his physical dependence, a state rooted in a different part of the brain: the Locus Coeruleus (LC).¹⁸ The LC is the brain’s primary source of noradrenaline (NA), a neurotransmitter that regulates wakefulness, alertness, blood pressure, and breathing. Opioids suppress the LC’s activity, which is why they cause drowsiness and slowed breathing. In response to chronic suppression, the LC neurons adapt by becoming hyperactive, working overtime to produce normal levels of NA even when the drug is present. This is a state of compensated, drug-dependent homeostasis.¹⁸

The true horror of this adaptation is revealed when the drug is withdrawn. When Alex missed a dose or tried to stop, the powerful suppressive effect of the opioid was suddenly gone. His now-hyperactive LC, with no chemical brake, unleashed a massive flood of noradrenaline throughout his brain and body. This is the storm of withdrawal. It manifested as profound anxiety, uncontrollable jitters, drenching sweats, and painful muscle cramps. His nose ran constantly (rhinorrhea), and he was wracked with diarrhea.⁶ The physical misery was compounded by an overwhelming psychological craving for the one thing that could make it stop. He was no longer using to feel good; he was using to stop feeling unimaginably bad.²⁵ This is the trap of dependence: the drug becomes its own, and only, solution.

This entire process—the hijacking of reward, the compulsive drive, the reprogramming of survival instincts to serve a chemical—can be understood through a powerful and scientifically grounded metaphor. The addiction itself begins to function like a behavioral parasite. It is a non-sentient process, yet it operates with a singular, parasitic goal: its own propagation, which means ensuring the host consumes more of the drug. It rewires the host’s brain, co-opting the fundamental machinery of learning, motivation, and survival for its own ends.²² It severs the host’s connections to competing interests—family, work, health, other sources of pleasure—to consolidate its control, explaining the egocentric and isolating behaviors that are hallmarks of the disorder.²⁷ From this perspective, the idea that Alex could simply use “willpower” to quit is nonsensical. One cannot will away a parasite that has burrowed into the core of one’s operating system and rewritten the code. His struggle was not with himself; it was with an invisible, parasitic process that had seized control of his brain.

Chapter 2: The Body’s Betrayal: The Physiology of Long-Term Use

Years passed. Alex’s life narrowed until it was defined by a grim, repeating cycle: obtaining the drug, using the drug, and recovering from the drug.¹⁵ The initial prescription for OxyContin had long ago become a gateway. When doctors became wary of his “drug-seeking behavior,” he turned to the illicit market, where heroin was cheaper and more readily available.¹ Later, the even more potent and unpredictable synthetic opioid, fentanyl, began to contaminate the supply.²⁹ The athlete’s body he once inhabited became a vessel for the addiction, and the long-term use began to exact a devastating physiological price, a systemic betrayal that went far beyond the immediate intoxication or withdrawal.

One of the most constant and debilitating companions of his chronic opioid use was severe gastrointestinal distress. Opioids exert a powerful slowing effect on the entire digestive system by acting on the nerves that control gut motility. For Alex, this meant chronic, painful constipation that became a central feature of his daily life.¹¹ The condition was more than just an uncomfortable side effect; it led to persistent bloating, agonizing abdominal cramps, and a constant risk of developing a complete bowel obstruction, a life-threatening medical emergency.¹¹ This unrelenting physical discomfort also took a psychological toll, as studies have shown a direct link between chronic opioid-induced constipation and an increased risk of psychological distress and depression, adding another layer of misery to his existence.³¹

Even more insidiously, the drugs were silently dismantling his endocrine system. Chronic opioid use is known to disrupt the delicate balance of the body’s hormonal pathways, particularly the hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-gonadal (HPG) axis.³² For Alex, this manifested as opioid-induced hypogonadism. His testosterone levels plummeted, leading to a cascade of debilitating symptoms: a near-total loss of libido, erectile dysfunction, crushing fatigue that no amount of sleep could fix, and a deepening depression.¹¹ This hormonal collapse provided a direct biological explanation for the erosion of his intimate relationships; the drug had chemically extinguished the very desires that foster human connection.²⁷ For women with OUD, these endocrine effects are just as severe, often causing amenorrhea (the cessation of menstruation) and infertility.³²

His body’s defenses were also crumbling. Research from both human and animal studies has demonstrated that opioids have a profound immunomodulating effect, suppressing the function of critical immune cells and weakening the body’s ability to fight off invaders.³² This immunosuppression left Alex vulnerable to frequent infections. When combined with the high-risk behaviors that often accompany injection drug use, such as sharing needles, this compromised immunity created a perfect storm for contracting serious infectious diseases. The risk of acquiring HIV or hepatitis C, already elevated by the mode of use, was amplified by a body less capable of mounting a defense.⁵

Perhaps the most cruel and paradoxical betrayal of all was the onset of opioid-induced hyperalgesia (OIH). The very class of drugs Alex had first taken to relieve pain now caused him to experience more pain.³² OIH is a complex neurological phenomenon in which long-term opioid exposure leads to neuroplastic changes in the peripheral and central nervous systems, resulting in a state of abnormal, heightened pain sensitivity.³² The pain he now felt was different from his original injury; it was a diffuse, ill-defined ache that seemed to permeate his entire body. In a desperate attempt to find relief, he would increase his opioid dose, but this only fueled the fire, worsening the hyperalgesia in a vicious, inescapable cycle.³²

The damage was systemic. His liver and kidneys, forced to process the constant stream of drugs—often cut with unknown substances and, in the case of many prescription pills, combined with high doses of acetaminophen—were under immense strain, putting him at risk for long-term damage and even failure.³⁰ His cardiovascular system was also in jeopardy, with studies linking long-term opioid use to an increased risk of serious cardiac events, including myocardial infarction and heart rhythm abnormalities like atrial fibrillation.¹¹ Furthermore, the cognitive and sensory-motor impairment caused by the drugs made him clumsy and uncoordinated, leading to frequent falls and an elevated risk of fractures, a danger comparable to that associated with benzodiazepines.¹¹ Alex’s body was no longer his own; it was a battleground, ravaged by the very substance he believed he needed to survive.

The stark contrast between the drug’s initial allure and its long-term consequences illustrates the fundamental deception at the heart of opioid addiction. The following table captures this “bait and switch,” juxtaposing the seductive promise of the first dose with the devastating betrayal of chronic use.

Table 1: The Two Faces of Opioid Use: The Promise vs. The Betrayal

The Promise (Initial/Short-Term Effects)	The Betrayal (Chronic/Long-Term Harms)
Euphoria & Elevated Mood 5	Neurological: Addiction/OUD 15, Anhedonia 37, Cognitive Decline 5, Opioid-Induced Hyperalgesia 32, Seizures 5
Profound Pain Relief 11	Physiological: Chronic Constipation/Bowel Obstruction 11, Endocrine Disruption (Hypogonadism, Infertility) 32, Immunosuppression & Infectious Disease Risk 5, Liver & Kidney Damage 30, Cardiovascular Events 11
Relaxation & Drowsiness 30	Psychological: Depression, Anxiety Disorders, Paranoia, Psychosis 5
Sense of Calm & Well-being	Social: Isolation, Destroyed Relationships 27, Unemployment 27, Legal & Financial Ruin 5, Homelessness 27

Chapter 3: The Mind’s Prison: Neurological and Psychological Decay

While Alex’s body was breaking down, his internal world was collapsing. The long-term assault of opioids on his brain was not just rewiring his motivation; it was fundamentally altering his capacity for thought, emotion, and pleasure, trapping him in a psychological prison of monochrome misery.

The most profound change was the creeping onset of anhedonia, the clinical term for the inability to experience pleasure.³⁷ The vibrant world of his youth—the joy of a shared laugh, the satisfaction of a task well done, the simple pleasure of a good meal—had faded to gray. Nothing felt good anymore, except the drug. And even that was a pale imitation of the original high, a fleeting moment of “not-bad” in an endless sea of bleakness. This is a direct and predictable consequence of hijacking the brain’s reward system. After years of being flooded with artificial, drug-induced dopamine, the system becomes desensitized and hypo-functional.⁴¹ Natural rewards, with their comparatively gentle dopamine release, can no longer register. The brain’s complex calculus of effort versus reward becomes hopelessly skewed: every activity feels like a monumental effort, while the potential reward feels negligible or non-existent.⁴² Anhedonia is a core driver of relapse. When the world offers no pleasure, the memory of the drug’s artificial vibrancy becomes an almost irresistible siren song, promising a temporary escape from the gray emptiness.³⁷

This state of profound apathy is further explained by the pathological hijacking of the brain’s SEEKING system. First described by neuroscientist Jaak Panksepp, the SEEKING system is a primary emotional drive, an ancient, dopamine-fueled engine of curiosity, exploration, and goal-directed behavior.⁴³ In a healthy individual, this system is versatile and flexible, motivating the search for all manner of resources, from food and shelter to knowledge and social connection. In addiction, however, this powerful system becomes pathologically “fixated” on a single, all-consuming target: the drug.⁴³ Alex’s entire motivational life force, his innate drive to engage with the world, was now channeled into a rigid, obsessive-compulsive loop of thinking about, obtaining, and using opioids. This fixation explains the devastating “tunnel vision” of addiction, the profound and baffling disinterest in everything that is not the object of dependence.¹⁵ His mind, once capable of complex thought and varied interests, was now imprisoned in a singular, repetitive pursuit.

This mental narrowing was compounded by a more general cognitive decline. The constant presence of opioids in his system created a persistent mental fog. He struggled to concentrate, his thoughts felt sluggish and disjointed, and his memory became unreliable.⁵ Scientific research confirms this subjective experience, showing that chronic opioid exposure leads to measurable impairments in key cognitive functions, most notably working memory—the ability to hold and manipulate information in the short term.³⁸ This is a critical deficit because working memory is essential for nearly all higher-order cognitive activities, including problem-solving, planning, and self-regulation. The cognitive damage caused by addiction is therefore not merely a side effect; it is a direct impediment to recovery. It sabotages the very mental tools a person needs to engage effectively in therapy, learn new coping skills, and make the complex decisions required to rebuild a life.³⁸

As Alex’s internal and external worlds shrank, his psychological state disintegrated. The chronic stress, the shame, the isolation, and the direct neurochemical effects of the drugs created a fertile ground for co-occurring mental illnesses. Like many with OUD, he developed severe depression and a crippling anxiety disorder.⁶ This ignited a devastating feedback loop, a downward spiral of immense destructive power. The emotional pain of his depression and anxiety drove him to use more opioids in a desperate attempt to self-medicate and numb the feelings. But the opioids themselves, through their disruption of brain chemistry and the chaos they created in his life, only served to worsen the underlying mental illness.³¹ He was trapped in a cycle where the “solution” was also the poison, each dose digging him deeper into a pit of psychological despair.

Chapter 4: The Great Unraveling: The Social Consequences

The internal decay, the physical betrayal and psychological imprisonment, inevitably spilled outward, unraveling the fabric of Alex’s life. The social consequences of his opioid use disorder were not secondary effects; they were the external manifestation of the disease, a relentless process of disconnection that left him isolated and adrift.

The first threads to break were his closest relationships. The person his family and friends once knew began to disappear, replaced by a stranger driven by the singular, secret need for the drug. The disease is inherently corrosive to social bonds.²⁷ Honesty was replaced by lies to cover up his use. Trust was shattered by theft—money from his mother’s purse, valuables from the family home—all pawned to finance his escalating habit.¹ He became a ghost in his own life, neglecting his responsibilities, missing family events, and failing at work until he was fired.⁵ His social network, once a source of strength and identity, began to fray and reconfigure. Old friends, unable to watch his self-destruction, pulled away. He, in turn, withdrew from them, finding their sober lives a painful reminder of what he had lost. His world shrank until it consisted mainly of other people caught in the same cycle, an unstable and transient network built on a shared desperation.²⁷

This retreat into isolation is one of the most defining and dangerous features of opioid addiction. There is a powerful, bidirectional relationship between social isolation and opioid use—each one feeds and exacerbates the other.²⁷ The brain’s own endogenous opioid system is fundamentally involved in the neurochemistry of social bonding and attachment; it’s what makes connection feel good. When exogenous opioids like heroin or fentanyl are introduced, they can create a temporary, artificial sense of comfort and emotional well-being, a chemical substitute for genuine human connection. This can reduce the motivation to seek out and maintain real relationships, leading to greater social isolation. The profound loneliness and pain that result from this isolation then become powerful triggers for more drug use, creating a vicious cycle.²⁷ Alex increasingly used alone, a practice that is tragically common and exceptionally deadly. With no one present to administer the overdose-reversal drug naloxone, a solitary user who overdoses has almost no chance of survival. More than half of all fatal opioid overdoses occur when the person is alone.²⁷

This individual unraveling is mirrored at a societal level. Alex’s story became one of millions. He lost his job, joining the ranks of the unemployed, a status vastly overrepresented among people with OUD.²⁷ His efforts to support his addiction led to arrests for petty crime, entangling him in the criminal justice system—a common trajectory for those with the disease.⁵ He became a target of the profound social stigma that surrounds addiction. Instead of being seen as a person suffering from a brain disease, he was viewed by many as a “junkie,” a person with a moral failing who was simply unwilling to stop.²⁷ This stigma is not just hurtful; it is a formidable barrier that prevents countless individuals from seeking the medical treatment they desperately need.²⁷

When we zoom out from Alex’s individual tragedy, we see a broader tear in the social fabric. Researchers have documented a direct correlation between the opioid epidemic and a decline in what sociologists call “social capital”—the networks of relationships, shared values, and trust that bind communities together. Geographic data starkly illustrates this connection: in places like West Virginia, the counties with the highest rates of drug overdose deaths are also the ones with the lowest levels of social capital.²⁷ The opioid crisis, therefore, is not merely a collection of individual stories of addiction. It is a symptom and a cause of a deeper social malaise, a crisis of connection that has left both individuals and entire communities fragmented and vulnerable. Alex was not just losing his own life; he was a single data point in the story of a society coming apart.

Part II: The Epiphany – The Bottom of the Well

Chapter 5: The Moment of Fracture

There is a point in the descent where the darkness becomes absolute. For Alex, it was not a single, dramatic event but a confluence of failures, a moment when the accumulated weight of his ruined life became too heavy to bear. The “rock bottom” was the bottom of a well he had dug for himself, one dose at a time. The final fracture came on a Tuesday afternoon in the grimy bathroom of a gas station. He had just injected a dose of what he thought was heroin but was likely laced with fentanyl. Instead of the familiar rush, a terrifying coldness spread through his chest. His breathing became shallow, a desperate, ragged panting. The room began to spin, the edges of his vision dissolving into black. He collapsed, his head hitting the tiled floor with a dull thud. He was dying. By sheer, dumb luck, another person entered the bathroom moments later, saw his blue-tinged lips, and called 911. The paramedics arrived and administered two doses of naloxone, the opioid antagonist that violently rips the drug from the brain’s receptors, shocking the system back to life.²

Alex gasped awake not to a gentle dawn but to the blinding fluorescent lights of the bathroom, the concerned faces of strangers, and the excruciating agony of precipitated withdrawal. The naloxone had saved his life, but it had also plunged him into the deepest pit of withdrawal he had ever known. As he lay shivering on the floor, every cell in his body screaming in protest, he saw his reflection in a shard of a broken mirror. He did not recognize the person staring back: a gaunt, hollow-eyed stranger with track marks scarring his arms.¹ In that moment of profound physical and existential horror, the illusion shattered. He was not a recreational user. He was not in control. He was a slave to a chemical, and it had nearly killed him. This was not living; it was a slow-motion suicide.

This harrowing moment of clarity, the narrative “rock bottom,” is the subjective, lived experience of a profound neurobiological shift. It is the moment a person with OUD is forced to confront what addiction expert George Koob has termed the “dark side” of addiction.⁵⁰ The brain’s motivation for drug use undergoes a fundamental transformation over time. The initial stages of addiction are driven primarily by positive reinforcement: the user seeks the drug to experience the intense pleasure of the high. But as the disease progresses, the motivation shifts to one dominated by negative reinforcement.⁵⁰ The user is no longer chasing pleasure; they are desperately trying to escape the pervasive, all-encompassing misery of the “anti-reward” state.

This state is the brain’s long-term adaptation to chronic drug use. It is defined by two core processes: a severe downregulation and dysfunction of the brain’s natural reward systems, and a simultaneous hyper-activation of the brain’s stress systems, including those in the extended amygdala.⁵⁰ The result is a persistent, agonizing state of negative emotion—a condition Koob and his colleagues term “hyperkatifeia,” which translates roughly to an excessive state of misery.⁵⁰ This is the source of the chronic irritability, the emotional and physical pain, the deep dysphoria, and the anhedonia that define the daily reality of long-term addiction. The drug is no longer a source of joy; it is a temporary, and increasingly ineffective, anesthetic for a pain that the drug itself has created and now perpetuates.

Alex’s epiphany on the gas station floor was the moment this biological reality became his conscious reality. The intricate web of denial and rationalization he had woven for years was torn apart by the raw, undeniable truth: the drug was not his friend, his escape, or his solution. It was his tormentor. The “high” was a lie, a fleeting moment of relief in an endless cycle of self-inflicted pain. The decision to seek help, which came in a broken whisper to the paramedic, was not a sudden surge of heroic willpower. It was a cognitive and emotional surrender. It was the only logical choice left for a mind that, however weakened, could finally process the overwhelming evidence that the current path led only to the grave. It was a moment of desperate, painful clarity, born from the absolute depths of his misery.

Part III: The Solution – The Long Climb Back

Chapter 6: The Science of Healing: Reclaiming the Brain

The journey out of the well began not with a grand gesture, but with a phone call to a treatment center. Alex took the first, terrifying step into a world he had long avoided, a world that promised a different path but demanded a confrontation with the wreckage he had made of his life. He learned quickly that the popular notions of recovery—that one must simply “tough it out” or go “cold turkey”—were not just wrong, they were dangerous myths.²⁵ Quitting opioids abruptly without medical support is associated with such severe withdrawal symptoms and intense cravings that the risk of immediate relapse and subsequent overdose is extraordinarily high.⁵² Recovery from a brain disease, he was told, requires medical intervention to heal the brain.

The cornerstone of his treatment was Medication-Assisted Treatment (MAT), the gold standard of care for Opioid Use Disorder.³⁴ He was prescribed buprenorphine, a medication that would become his lifeline. The science behind MAT is elegant and powerful. Medications like buprenorphine (a partial opioid agonist) and methadone (a full opioid agonist) work by binding to the same mu-opioid receptors in the brain that heroin and fentanyl target. However, they do so in a controlled, long-acting manner. This action effectively normalizes the brain’s chaotic chemistry. It eliminates the agonizing symptoms of withdrawal, extinguishes the relentless physiological cravings, and, because the receptors are occupied, blocks the euphoric effects of any illicit opioids he might use.³⁴ Another MAT option, naltrexone, works differently as an opioid antagonist, completely blocking the receptors so that no opioid can produce an effect.³⁴

In the clinic, Alex had to confront one of the most pervasive and damaging stigmas in addiction treatment: the myth that MAT is simply “substituting one addiction for another”.²⁵ His counselor patiently explained the critical distinction between physical dependence and addiction. While MAT medications do cause physical dependence (meaning a person would experience withdrawal if they stopped abruptly), they do not cause the compulsive, destructive, and life-ruining behaviors that define addiction.²⁵ Buprenorphine did not make him high; it made him feel normal. It quieted the noise in his brain. For the first time in years, he was not consumed by the need to find and use drugs. The medication was not a crutch; it was a platform. It stabilized his brain, allowing him to stop the destructive behaviors and finally begin the hard psychological work of recovery.⁴⁹ The evidence for this approach is overwhelming. Decades of research have shown that MAT dramatically improves survival rates, significantly reduces illicit drug use and criminal activity, lowers the risk of overdose death, and helps people stay in treatment long enough for it to be effective.³⁴

With his brain chemistry stabilized by MAT, Alex could begin to engage in therapy. He started individual and group sessions of Cognitive Behavioral Therapy (CBT), a structured, goal-oriented psychotherapy designed to rewire the maladaptive thoughts and behaviors that fueled his addiction.⁵⁸ In his CBT sessions, he learned, for the first time, to systematically identify his triggers—the specific people, places, feelings, and situations that sparked his cravings.⁵⁸ He and his therapist worked to develop practical coping skills to manage these triggers when they arose. A core component of the therapy was learning to recognize and challenge the automatic negative thoughts and false beliefs that had become ingrained in his thinking. The thought “I’m a failure, I’ll never get better, so I might as well use” was painstakingly deconstructed and reframed into a more balanced and realistic thought: “Recovery is difficult and I may have setbacks, but I am capable of making progress”.⁶⁰ He also worked on a “pleasant activity schedule,” consciously planning and engaging in small, healthy activities—a walk in the park, listening to music, calling a friend—to begin the long process of retraining his brain to experience natural pleasure and rewards again.⁶⁰

His outpatient program also incorporated Contingency Management (CM), a form of behavioral therapy grounded in the principles of operant conditioning.⁶² The premise was simple but effective: he received tangible, immediate rewards for meeting specific treatment goals. Each time he provided a urine sample that tested negative for illicit drugs, he earned the chance to draw from a fishbowl full of slips of paper, some of which were redeemable for prizes like gift cards for groceries or movie tickets.⁶² This system provided immediate, positive reinforcement for the healthy behavior of abstinence, directly countering the brain’s learned association between action and the immediate (but destructive) reward of the drug. Research has shown that CM, especially when used in combination with MAT and CBT, is a highly effective intervention for increasing treatment retention and promoting abstinence.⁶²

These evidence-based treatments formed the scientific foundation of Alex’s recovery. They were not moral tests or exercises in willpower; they were targeted interventions designed to heal a diseased organ and rebuild a life. The table below provides a clear overview of these core modalities, demystifying the science of recovery.

Table 2: Evidence-Based Pathways to Recovery: A Comparative Overview

Treatment Modality	Mechanism of Action	Primary Goals	Key Evidence & Supporting Snippets
Medication-Assisted Treatment (MAT)	Opioid agonist or antagonist action stabilizes brain chemistry and opioid receptors.	Reduce cravings; prevent withdrawal; block euphoric effects; reduce overdose risk; improve treatment retention and survival.	25
Cognitive Behavioral Therapy (CBT)	Identifies and restructures maladaptive thought patterns, beliefs, and behaviors.	Develop coping skills; manage triggers; address co-occurring disorders (anxiety, depression, chronic pain).	58
Contingency Management (CM)	Principles of operant conditioning; provides tangible positive reinforcement for desired behaviors.	Encourage abstinence; improve treatment attendance and medication adherence; build healthy habits.	62

Chapter 7: Choosing to Climb: The Architecture of a New Life

Recovery, Alex discovered, was not a destination. There was no graduation ceremony, no moment of final cure. It was, instead, the beginning of a new way of living, a continuous process of management, vigilance, and growth. The path forward was not a straight line; it was a rugged, uphill climb with switchbacks, loose gravel, and the constant possibility of a misstep.¹⁵

The greatest danger lay in re-entering his old life. The brain, with its powerful capacity for learning, had forged deep and lasting connections between his drug use and countless environmental cues.¹⁷ The sight of a particular street corner, the voice of an old acquaintance on the phone, a wave of stress or boredom—these seemingly innocuous triggers could unleash a tidal wave of craving, a conditioned response that was automatic and visceral.¹⁷ This is why relapse is such a common feature of the disease, and why aftercare and ongoing support are not optional extras but essential components of long-term success.

He found strength in a metaphor from the story of another person in recovery, Rachel George, who described her journey as a daily choice to “climb instead of fall”.⁴⁶ This resonated deeply. Each morning, he had to make a conscious choice to engage with the tools of his recovery. It required immense mental fortitude to navigate a world still laden with triggers while his brain was slowly, painstakingly healing. The anhedonia lingered for months, a persistent grayness that tested his resolve. But with the support of his treatment team and the stability provided by his medication, moments of color began to return. The taste of coffee. The warmth of the sun. A genuine laugh. Each one was a small victory, evidence that his brain’s reward system was beginning to stir back to life.

The core of his recovery was the slow, deliberate work of rebuilding the life his addiction had demolished. It began with his family. His parents and sister entered family counseling, learning about the neurobiology of addiction and developing their own strategies for healing from the trauma his disease had inflicted on them.⁶⁷ Mending those broken bonds was a slow process, built on a foundation of consistent, honest action on his part. Trust, he learned, is not rebuilt with words, but with time and changed behavior.

Finding meaningful work was another critical pillar. With the help of a vocational support program, he found a job in a warehouse. The work was physically demanding, but the routine and the responsibility were grounding. It gave him a reason to get up in the morning and provided a structure that left less empty time for his mind to wander into dangerous territory.⁶¹ More importantly, it allowed him to start building a new, sober social network, a crucial element in reducing the isolation that fuels addiction.²⁷

He also found a profound sense of community in peer support groups.⁶⁶ Sitting in a room with other people who understood his struggle without judgment was a powerful antidote to the shame and isolation he had carried for so long. Sharing his story and listening to the stories of others reinforced the reality that he was not alone, that he was suffering from a shared disease, and that recovery, while difficult, was possible. This process of rebuilding social connections is not just a psychological comfort; it is a neurobiologically vital part of healing. Improving social integration through stable housing, employment, and meaningful relationships is one of the most effective ways to support long-term recovery and decrease drug use.²⁷

Through this process, Alex came to understand a fundamental truth articulated by addiction scientist Alan Leshner: a person who has been truly addicted has crossed a neurological threshold and entered a different state of being.¹⁷ There is no going back. The idea of a successful return to “occasional use” is, for the vast majority, a dangerous fantasy. Recovery is not about erasing the past or becoming the person he was before. It is about learning to live a full, rich, and meaningful life within this new reality, managing a chronic but treatable brain condition with the same vigilance and commitment one would bring to managing diabetes or heart disease. It is the architecture of a new life, built brick by brick, day by day.

Conclusion: A Dose of Reality, A Measure of Hope

Alex’s journey—from the deceptive comfort of the first dose to the bleak landscape of long-term dependence, from the terrifying nadir of a near-fatal overdose to the arduous, hopeful climb of recovery—is more than a single story. It is a microcosm of a national tragedy, a story that has played out in millions of lives across every demographic and corner of the country. His experience illuminates a set of crucial, evidence-based truths that must form the foundation of our collective response to the opioid crisis.

First, his story demonstrates with painful clarity that Opioid Use Disorder is a brain disease, not a character flaw or a moral failing.¹⁷ The compulsive drug-seeking, the lies, the betrayal of trust—these are not choices made by a bad person, but symptoms of a hijacked brain, an organ whose fundamental circuits of learning, motivation, and survival have been pathologically rewired by a powerful chemical. To blame the individual for these behaviors is as illogical and cruel as blaming a person with schizophrenia for their hallucinations or a person with Alzheimer’s for their memory loss.¹⁷

Second, his journey reveals that the roots of this disease are complex, extending far beyond individual biology. The crisis was ignited by a calculated campaign of corporate greed and deception that weaponized the trust of the medical system, and it has been sustained by societal factors like social isolation, economic despair, and a profound stigma that isolates sufferers and bars them from care.³ Alex’s vulnerability as a teenager in pain intersected with a system primed to offer a dangerous and misleading solution. He was not just a patient; he was a consumer, targeted by a marketing strategy of devastating effectiveness.

Finally, and most importantly, his recovery shows that while the damage of this disease is profound, it is not a hopeless condition. Hope, however, must be grounded in a dose of reality—the reality of science. The path forward, for both individuals and society, must be paved with evidence-based solutions that address the multifaceted nature of the illness.

At the individual level, this means ensuring universal, low-barrier access to compassionate and comprehensive treatment. This must include the full spectrum of evidence-based care: Medication-Assisted Treatment to stabilize the brain, behavioral therapies like CBT and CM to rewire thoughts and reinforce healthy behaviors, and integrated care for the co-occurring mental and physical health conditions that almost always accompany OUD.⁶

At the community level, the work involves dismantling the stigma that has been a major accelerant of this crisis. This requires public education that reframes addiction as a medical condition and the use of person-first language that affirms dignity (“a person with substance use disorder,” not an “addict”).⁴⁹ It also requires a concerted effort to rebuild the social capital that has been eroded, creating supportive environments through peer-led recovery centers, stable housing opportunities, and pathways to meaningful employment.²⁷

And at the systemic level, it demands unwavering accountability for the corporate and institutional actors who created and profited from the crisis, alongside the implementation of robust public health policies and regulations to prevent such a catastrophe from ever happening again.

The long night of opioid addiction has inflicted an almost unimaginable toll on individuals, families, and communities. But as the stories of Alex and the countless real people in recovery like him demonstrate, a new dawn is possible. The climb is long, and the scars may never fully fade. Yet through a steadfast commitment to science, a radical embrace of compassion, and the recognition that we are all connected in this struggle, lives can be, and are being, rebuilt. The resilience of the human spirit, when supported by the tools of modern medicine and the strength of community, can ultimately prove more powerful than the invisible hook of the drug.

Works cited

1. Hope after Heroin: Stories of Recovery | Hartford HealthCare | CT, accessed on August 12, 2025, https://hartfordhealthcare.org/about-us/connect-to-healthier/hope-after-heroin
2. Student shares story of opioid addiction to support others, accessed on August 12, 2025, https://csua.ssri.psu.edu/news/student-shares-story-opioid-addiction-support-others
3. New book sheds light on secretive Sackler family — the makers of …, accessed on August 12, 2025, https://www.pbs.org/newshour/show/new-book-sheds-light-on-secretive-sackler-family-the-makers-of-opioid-oxycontin
4. Purdue Pharma | EBSCO Research Starters, accessed on August 12, 2025, https://www.ebsco.com/research-starters/history/purdue-pharma
5. Drug addiction (substance use disorder) – Symptoms and causes …, accessed on August 12, 2025, https://www.mayoclinic.org/diseases-conditions/drug-addiction/symptoms-causes/syc-20365112
6. Opioid Use Disorder – Psychiatry.org, accessed on August 12, 2025, https://www.psychiatry.org/patients-families/opioid-use-disorder
7. Opioid Epidemic | Maricopa County Attorney’s Office, AZ, accessed on August 12, 2025, https://maricopacountyattorney.org/396/Opioid-Epidemic
8. Focus on Opioids – Connect2Health FCC, accessed on August 12, 2025, https://www.fcc.gov/reports-research/maps/connect2health/focus-on-opioids.html
9. What led to the opioid crisis—and how to fix it | Harvard T.H. Chan School of Public Health, accessed on August 12, 2025, https://hsph.harvard.edu/news/what-led-to-the-opioid-crisis-and-how-to-fix-it/
10. Sackler family – Wikipedia, accessed on August 12, 2025, https://en.wikipedia.org/wiki/Sackler_family
11. Long-Term Opioid Therapy Reconsidered – PMC, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3280085/
12. Understanding the Opioid Epidemic – PBS, accessed on August 12, 2025, https://www.pbs.org/video/understanding-the-opioid-epidemic-oei0dd/
13. Heroin and Opioid Addiction, Prevention, and Training – College of Southern Maryland, accessed on August 12, 2025, https://www.csmd.edu/student-services/health-wellness/heroin-and-opioid-addiction/index.html
14. Opioids, Inc. | FRONTLINE – PBS, accessed on August 12, 2025, https://www.pbs.org/wgbh/frontline/documentary/opioids-inc/
15. Opioid Use Disorder: Evaluation and Management – StatPearls …, accessed on August 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK553166/
16. Is Addiction a Disease? Science Says Yes – Michigan Medicine, accessed on August 12, 2025, https://www.michiganmedicine.org/health-lab/science-says-addiction-chronic-disease-not-moral-failing
17. Addiction Is a Brain Disease – Issues in Science and Technology, accessed on August 12, 2025, https://issues.org/leshner/
18. The Neurobiology of Opioid Dependence: Implications for Treatment – PubMed Central, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2851054/
19. The Myth of Willpower: Why Addiction is More Than Just a Choice in Miami, accessed on August 12, 2025, https://www.cpccenters.com/the-myth-of-willpower-why-addiction-is-more-than-just-a-choice-in-miami/
20. Why our brains are wired for addiction: What the science says, accessed on August 12, 2025, https://med.stanford.edu/news/insights/2025/08/addiction-science-human-brain-ancient-wiring.html
21. The Neuroscience of Drug Reward and Addiction – PMC – PubMed Central, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6890985/
22. Addiction: a disease of learning and memory – PubMed, accessed on August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/16055762/
23. The Science Behind Addiction: A Deep Dive into the Hijacked Brain – Rainford Hall, accessed on August 12, 2025, https://rainfordhall.com/blog/the-science-behind-addiction-a-deep-dive-into-the-hijacked-brain/
24. About Prescription Opioids | Overdose Prevention – CDC, accessed on August 12, 2025, https://www.cdc.gov/overdose-prevention/about/prescription-opioids.html
25. 10 Harmful Myths About Medication-Assisted Treatment | MedMark, accessed on August 12, 2025, https://medmark.com/resources/blog/10-harmful-myths-about-medication-assisted-treatment
26. How Drugs and Behaviors Hijack the Brain – The National Judicial College, accessed on August 12, 2025, https://www.judges.org/news-and-info/how-drugs-and-behaviors-hijack-the-brain/
27. role of social isolation in opioid addiction | Social Cognitive and …, accessed on August 12, 2025, https://academic.oup.com/scan/article/16/7/645/6157894
28. Neuropathology of substance use disorders – PMC – PubMed Central, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7453825/
29. Opioid Use Disorder – Johns Hopkins Medicine, accessed on August 12, 2025, https://www.hopkinsmedicine.org/-/media/johns-hopkins-bayview/myths-about-opioid-use-disorder.pdf
30. Physical Health Risks of Opioid Use: Short- and Long-Term Consequences, accessed on August 12, 2025, https://lakecountyin.gov/departments/health/Nursing-Clinic/Prevention/Opioids/physical-health-risks-of-opioid-use-short-and-long-term-consequences
31. Long- & Short-Term Health Effects of Opioid Use & Addiction | AdCare, accessed on August 12, 2025, https://adcare.com/opioids/long-term-use/
32. Long term harms of opioids | Faculty of Pain Medicine, accessed on August 12, 2025, https://fpm.ac.uk/opioids-aware-clinical-use-opioids/long-term-harms-opioids
33. Drug Abuse and Parasitic Diseases: A Public Health and Social Challenge – ResearchGate, accessed on August 12, 2025, https://www.researchgate.net/publication/382550874_Drug_Abuse_and_Parasitic_Diseases_A_Public_Health_and_Social_Challenge
34. An Overview of Medication-Assisted Treatment for Opioid Use Disorders for Criminal Justice-Involved Individuals, accessed on August 12, 2025, https://icjia.illinois.gov/researchhub/articles/an-overview-of-medication-assisted-treatment-for-opioid-use-disorders-for-criminal-justice-involved-individuals
35. Adverse effects of opioids on the central nervous systems of palliative care patients – PubMed, accessed on August 12, 2025, https://pubmed.ncbi.nlm.nih.gov/17430825/
36. The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop | Annals of Internal Medicine – ACP Journals, accessed on August 12, 2025, https://www.acpjournals.org/doi/10.7326/M14-2559
37. Anhedonia and Substance Dependence: Clinical Correlates and …, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3089992/
38. Retraining the Brain After Chronic Opioid Exposure – Recovery Research Institute, accessed on August 12, 2025, https://www.recoveryanswers.org/research-post/retraining-brain-chronic-opioid-exposure/
39. The Opioid Crisis: Impact, Challenges, and Paths to Recovery – Psychiatry.org, accessed on August 12, 2025, https://www.psychiatry.org/news-room/apa-blogs/opioid-crisis-impact-challenges-recovery
40. The Neurobiology of Anhedonia and Other Reward-Related Deficits – PMC, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3253139/
41. How Addiction Hijacks Your Brain – Discovery Point Retreat, accessed on August 12, 2025, https://discoverypointretreat.com/blog/how-addiction-hijacks-your-brain/
42. Anhedonia Your Brain’s Dopamine Thief | Psyclarity Health, accessed on August 12, 2025, https://psyclarityhealth.com/anhedonia-your-brains-dopamine-thief/
43. The SEEKING Drive and Its Fixation: A Neuro-Psycho-Evolutionary Approach to the Pathology of Addiction, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8406748/
44. An Evolutionary Framework to Understand Foraging, Wanting, and Desire: The Neuropsychology of the SEEKING System – Department of English, accessed on August 12, 2025, https://web.english.upenn.edu/~cavitch/pdf-library/Wright_and_Panksepp_Neuropsychology_of_the_SEEKING_System.pdf
45. The Brain Emotional Systems in Addictions: From … – Frontiers, accessed on August 12, 2025, https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2020.609467/full
46. ‘I choose to climb instead of fall’ | NIH MedlinePlus Magazine, accessed on August 12, 2025, https://magazine.medlineplus.gov/article/i-choose-to-climb-instead-of-fall
47. Opioid Use Disorder | Johns Hopkins Medicine, accessed on August 12, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/opioid-use-disorder
48. Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings – SAMHSA Library, accessed on August 12, 2025, https://library.samhsa.gov/sites/default/files/treatment-criminal-justice-pep19-matusecjs.pdf
49. 3 Major Myths About Opioid Addiction > News > Yale Medicine, accessed on August 12, 2025, https://www.yalemedicine.org/news/opioid-addiction-myths
50. The Dark Side of Addiction: The Horsley Gantt to Joseph Brady Connection – PMC, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6135258/
51. The neurobiology of addiction – PMC – PubMed Central, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6767400/
52. Opioid Myths – Prescription Drug Abuse Toolkit – Wyoming Prevention Depot, accessed on August 12, 2025, https://www.wyomingpreventiondepot.org/rxtoolkit/opioids-101/opioid-myths/
53. Medications for Substance Use Disorders – SAMHSA, accessed on August 12, 2025, https://www.samhsa.gov/substance-use/treatment/options
54. Medications for Opioid Use Disorder | National Institute on Drug Abuse – NIDA, accessed on August 12, 2025, https://nida.nih.gov/research-topics/medications-opioid-use-disorder
55. Medication Assisted Treatment – YES NM, accessed on August 12, 2025, https://yes.nm.gov/s/medication-assisted-treatment?language=en_US
56. Medication-Assisted Treatment for Opioid Dependence & Barriers to Implementation – CTN Dissemination Library, accessed on August 12, 2025, https://ctnlibrary.org/PDF/994.pdf
57. New NIDA Study Shows Medication Treatment for Opioid Addiction Can Help Prevent Overdose Death – BoardPrep Recovery, accessed on August 12, 2025, https://www.boardpreprecovery.com/rehab-blog/new-nida-study-shows-medication-treatment-for-opioid-addiction-can-help-prevent-overdose-death/
58. Opioid Use Disorder | Fact Sheet – ABCT, accessed on August 12, 2025, https://www.abct.org/fact-sheets/opiod-use-disorder/
59. Cognitive-Behavioral Therapy (CBT) for Substance Use Disorder, accessed on August 12, 2025, https://americanaddictioncenters.org/therapy-treatment/cognitive-behavioral-therapy
60. Cognitive Behavioral Therapy – Addiction Center, accessed on August 12, 2025, https://www.addictioncenter.com/treatment/cognitive-behavioral-therapy/
61. Alleviating Opioid Use Disorder With Cognitive Behavior Therapy and Medication-Assisted Treatment – Psychiatric Times, accessed on August 12, 2025, https://www.psychiatrictimes.com/view/alleviating-opioid-use-disorder-with-cognitive-behavior-therapy-and-medication-assisted-treatment
62. Using SAMHSA Funds To Implement Evidence-Based Contingency Management Services, accessed on August 12, 2025, https://library.samhsa.gov/sites/default/files/contingency-management-advisory-pep24-06-001.pdf
63. Contingency Management interventions for non-prescribed drug use during treatment for opiate addiction: A systematic review and meta-analysis, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5558146/
64. Contingency Management for Adults with Substance Use Disorder: Evidence Roundup, accessed on August 12, 2025, https://bettercareplaybook.org/_blog/2025/25/contingency-management-adults-substance-use-disorder-evidence-roundup
65. Rewarding recovery: the time is now for contingency management for opioid use disorder, accessed on August 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9045772/
66. Dose of Reality: Opioids Treatment and Recovery | Wisconsin …, accessed on August 12, 2025, https://www.dhs.wisconsin.gov/opioids/treatment-recovery.htm
67. 5 Types of Behavioral Therapy for Opioid Use Disorder – Solas Health, accessed on August 12, 2025, https://solas.health/blog/5-types-of-behavioral-therapy-for-oud/
68. Contingency Management for Treatment of Stimulant Use Disorder and Strategies to Address Polysubstance Use | Opioid Principles, accessed on August 12, 2025, https://opioidprinciples.jhsph.edu/contingency-management-for-treatment-of-stimulant-use-disorder-and-strategies-to-address-polysubstance-use/
69. Close to Home: Iowans Share Their Opiate Addiction Recovery Stories, accessed on August 12, 2025, https://www.ucsonline.org/resources-and-education/blog/national-recovery-month-sharing-personal-stories-of-opiate-addiction